nodes	percent_of_prediction	percent_of_DWPC	metapath
Naphazoline—Naftifine—Toremifene—breast cancer	0.444	0.614	CrCrCtD
Naphazoline—Naftifine—Tamoxifen—breast cancer	0.279	0.386	CrCrCtD
Naphazoline—NISCH—mammary gland—breast cancer	0.00425	0.114	CbGeAlD
Naphazoline—NISCH—nipple—breast cancer	0.00352	0.0943	CbGeAlD
Naphazoline—NISCH—Paclitaxel—Docetaxel—breast cancer	0.00252	0.358	CbGdCrCtD
Naphazoline—NISCH—uterus—breast cancer	0.00196	0.0525	CbGeAlD
Naphazoline—NISCH—pituitary gland—breast cancer	0.00192	0.0515	CbGeAlD
Naphazoline—NISCH—adipose tissue—breast cancer	0.00191	0.0513	CbGeAlD
Naphazoline—NISCH—Vincristine—Vinorelbine—breast cancer	0.00173	0.246	CbGdCrCtD
Naphazoline—NISCH—adrenal gland—breast cancer	0.00172	0.046	CbGeAlD
Naphazoline—NISCH—bone marrow—breast cancer	0.00166	0.0445	CbGeAlD
Naphazoline—ADRA2C—nipple—breast cancer	0.00161	0.0431	CbGeAlD
Naphazoline—NISCH—female gonad—breast cancer	0.0016	0.0429	CbGeAlD
Naphazoline—NISCH—Vinblastine—Vinorelbine—breast cancer	0.0014	0.198	CbGdCrCtD
Naphazoline—NISCH—Vincristine—Vinblastine—breast cancer	0.00139	0.197	CbGdCrCtD
Naphazoline—Eye disorder—Toremifene—breast cancer	0.00133	0.0078	CcSEcCtD
Naphazoline—Redness—Paclitaxel—breast cancer	0.0013	0.00758	CcSEcCtD
Naphazoline—ADRA2A—nipple—breast cancer	0.00128	0.0344	CbGeAlD
Naphazoline—Lacrimation—Docetaxel—breast cancer	0.00126	0.00737	CcSEcCtD
Naphazoline—Sweating—Anastrozole—breast cancer	0.00119	0.00697	CcSEcCtD
Naphazoline—Sweating—Letrozole—breast cancer	0.00119	0.00697	CcSEcCtD
Naphazoline—Vision blurred—Toremifene—breast cancer	0.00117	0.00685	CcSEcCtD
Naphazoline—Lacrimation increased—Irinotecan—breast cancer	0.00117	0.00681	CcSEcCtD
Naphazoline—ADRA1A—epithelium—breast cancer	0.00113	0.0304	CbGeAlD
Naphazoline—Sweating—Raloxifene—breast cancer	0.00113	0.00661	CcSEcCtD
Naphazoline—Lacrimation increased—Fluorouracil—breast cancer	0.00112	0.00652	CcSEcCtD
Naphazoline—Eye disorder—Ixabepilone—breast cancer	0.00111	0.00647	CcSEcCtD
Naphazoline—Keratitis—Capecitabine—breast cancer	0.00111	0.00647	CcSEcCtD
Naphazoline—Redness—Docetaxel—breast cancer	0.0011	0.00642	CcSEcCtD
Naphazoline—Eye disorder—Letrozole—breast cancer	0.00104	0.0061	CcSEcCtD
Naphazoline—NISCH—lymph node—breast cancer	0.00103	0.0276	CbGeAlD
Naphazoline—Hyperhidrosis—Fulvestrant—breast cancer	0.000994	0.00581	CcSEcCtD
Naphazoline—Headache—Fluoxymesterone—breast cancer	0.000987	0.00576	CcSEcCtD
Naphazoline—Hyperhidrosis—Toremifene—breast cancer	0.000981	0.00573	CcSEcCtD
Naphazoline—Erythema—Anastrozole—breast cancer	0.000972	0.00568	CcSEcCtD
Naphazoline—ADRA2C—endometrium—breast cancer	0.000969	0.026	CbGeAlD
Naphazoline—Terbinafine—CYP19A1—breast cancer	0.000959	0.248	CrCbGaD
Naphazoline—Tension—Anastrozole—breast cancer	0.000954	0.00557	CcSEcCtD
Naphazoline—Tension—Letrozole—breast cancer	0.000954	0.00557	CcSEcCtD
Naphazoline—Lacrimation increased—Paclitaxel—breast cancer	0.00095	0.00555	CcSEcCtD
Naphazoline—Hypertension—Exemestane—breast cancer	0.000945	0.00552	CcSEcCtD
Naphazoline—Nervousness—Anastrozole—breast cancer	0.000944	0.00552	CcSEcCtD
Naphazoline—Nervousness—Letrozole—breast cancer	0.000944	0.00552	CcSEcCtD
Naphazoline—Nausea—Fluoxymesterone—breast cancer	0.000935	0.00546	CcSEcCtD
Naphazoline—ADRA1A—adipose tissue—breast cancer	0.000917	0.0246	CbGeAlD
Naphazoline—Vision blurred—Letrozole—breast cancer	0.000916	0.00535	CcSEcCtD
Naphazoline—ADRA2C—uterus—breast cancer	0.000893	0.024	CbGeAlD
Naphazoline—ADRA2C—pituitary gland—breast cancer	0.000877	0.0235	CbGeAlD
Naphazoline—ADRA2C—adipose tissue—breast cancer	0.000874	0.0234	CbGeAlD
Naphazoline—Hyperhidrosis—Exemestane—breast cancer	0.000863	0.00504	CcSEcCtD
Naphazoline—Lacrimation—Epirubicin—breast cancer	0.000852	0.00497	CcSEcCtD
Naphazoline—Hypertension—Anastrozole—breast cancer	0.000839	0.0049	CcSEcCtD
Naphazoline—Hypertension—Letrozole—breast cancer	0.000839	0.0049	CcSEcCtD
Naphazoline—Hyperglycaemia—Goserelin—breast cancer	0.000823	0.00481	CcSEcCtD
Naphazoline—ADRA1A—adrenal gland—breast cancer	0.000822	0.0221	CbGeAlD
Naphazoline—Discomfort—Letrozole—breast cancer	0.000818	0.00478	CcSEcCtD
Naphazoline—Discomfort—Anastrozole—breast cancer	0.000818	0.00478	CcSEcCtD
Naphazoline—Sweating—Tamoxifen—breast cancer	0.000816	0.00477	CcSEcCtD
Naphazoline—Drowsiness—Goserelin—breast cancer	0.000813	0.00475	CcSEcCtD
Naphazoline—Lacrimation increased—Docetaxel—breast cancer	0.000805	0.00471	CcSEcCtD
Naphazoline—Asthenia—Lapatinib—breast cancer	0.000802	0.00469	CcSEcCtD
Naphazoline—Lacrimation—Doxorubicin—breast cancer	0.000788	0.0046	CcSEcCtD
Naphazoline—ADRA2C—adrenal gland—breast cancer	0.000784	0.021	CbGeAlD
Naphazoline—Lacrimation increased—Capecitabine—breast cancer	0.00078	0.00456	CcSEcCtD
Naphazoline—Sweating—Goserelin—breast cancer	0.00078	0.00455	CcSEcCtD
Naphazoline—ADRA2A—endometrium—breast cancer	0.000774	0.0207	CbGeAlD
Naphazoline—Keratitis—Epirubicin—breast cancer	0.000772	0.00451	CcSEcCtD
Naphazoline—Terbinafine—PTGS1—breast cancer	0.000772	0.199	CrCbGaD
Naphazoline—Hyperhidrosis—Letrozole—breast cancer	0.000767	0.00448	CcSEcCtD
Naphazoline—Hyperhidrosis—Anastrozole—breast cancer	0.000767	0.00448	CcSEcCtD
Naphazoline—Redness—Epirubicin—breast cancer	0.000742	0.00433	CcSEcCtD
Naphazoline—Asthenia—Fulvestrant—breast cancer	0.000738	0.00431	CcSEcCtD
Naphazoline—ADRA2C—female gonad—breast cancer	0.000731	0.0196	CbGeAlD
Naphazoline—Asthenia—Toremifene—breast cancer	0.000728	0.00425	CcSEcCtD
Naphazoline—Hyperhidrosis—Raloxifene—breast cancer	0.000728	0.00425	CcSEcCtD
Naphazoline—Keratitis—Doxorubicin—breast cancer	0.000714	0.00417	CcSEcCtD
Naphazoline—ADRA1A—endocrine gland—breast cancer	0.000713	0.0191	CbGeAlD
Naphazoline—ADRA2A—uterus—breast cancer	0.000713	0.0191	CbGeAlD
Naphazoline—Somnolence—Letrozole—breast cancer	0.000705	0.00412	CcSEcCtD
Naphazoline—Somnolence—Anastrozole—breast cancer	0.000705	0.00412	CcSEcCtD
Naphazoline—Eye pain—Paclitaxel—breast cancer	0.000704	0.00411	CcSEcCtD
Naphazoline—Hyperglycaemia—Thiotepa—breast cancer	0.000704	0.00411	CcSEcCtD
Naphazoline—Headache—Lapatinib—breast cancer	0.0007	0.00409	CcSEcCtD
Naphazoline—ADRA2A—pituitary gland—breast cancer	0.0007	0.0188	CbGeAlD
Naphazoline—ADRA2A—adipose tissue—breast cancer	0.000697	0.0187	CbGeAlD
Naphazoline—Redness—Doxorubicin—breast cancer	0.000686	0.00401	CcSEcCtD
Naphazoline—Eye disorder—Goserelin—breast cancer	0.000682	0.00399	CcSEcCtD
Naphazoline—Dizziness—Fulvestrant—breast cancer	0.00068	0.00397	CcSEcCtD
Naphazoline—Dizziness—Toremifene—breast cancer	0.000671	0.00392	CcSEcCtD
Naphazoline—Erythema—Tamoxifen—breast cancer	0.000665	0.00389	CcSEcCtD
Naphazoline—Nausea—Lapatinib—breast cancer	0.000664	0.00388	CcSEcCtD
Naphazoline—Headache—Fulvestrant—breast cancer	0.000644	0.00376	CcSEcCtD
Naphazoline—ADRA2A—female reproductive system—breast cancer	0.000641	0.0172	CbGeAlD
Naphazoline—Asthenia—Exemestane—breast cancer	0.000641	0.00374	CcSEcCtD
Naphazoline—Headache—Toremifene—breast cancer	0.000636	0.00371	CcSEcCtD
Naphazoline—Erythema—Goserelin—breast cancer	0.000636	0.00371	CcSEcCtD
Naphazoline—ADRA2A—adrenal gland—breast cancer	0.000625	0.0168	CbGeAlD
Naphazoline—Tension—Goserelin—breast cancer	0.000624	0.00364	CcSEcCtD
Naphazoline—Nervousness—Goserelin—breast cancer	0.000617	0.00361	CcSEcCtD
Naphazoline—Nausea—Fulvestrant—breast cancer	0.000611	0.00357	CcSEcCtD
Naphazoline—Hyperglycaemia—Mitoxantrone—breast cancer	0.000608	0.00355	CcSEcCtD
Naphazoline—Asthenia—Ixabepilone—breast cancer	0.000605	0.00353	CcSEcCtD
Naphazoline—Nausea—Toremifene—breast cancer	0.000603	0.00352	CcSEcCtD
Naphazoline—Drowsiness—Mitoxantrone—breast cancer	0.000601	0.00351	CcSEcCtD
Naphazoline—Vision blurred—Goserelin—breast cancer	0.000599	0.0035	CcSEcCtD
Naphazoline—Hyperglycaemia—Gemcitabine—breast cancer	0.000592	0.00346	CcSEcCtD
Naphazoline—Hypertension—Vinblastine—breast cancer	0.000591	0.00345	CcSEcCtD
Naphazoline—Dizziness—Exemestane—breast cancer	0.000591	0.00345	CcSEcCtD
Naphazoline—Eye disorder—Thiotepa—breast cancer	0.000584	0.00341	CcSEcCtD
Naphazoline—ADRA2A—female gonad—breast cancer	0.000583	0.0156	CbGeAlD
Naphazoline—Eye pain—Capecitabine—breast cancer	0.000578	0.00338	CcSEcCtD
Naphazoline—Discomfort—Vinblastine—breast cancer	0.000576	0.00337	CcSEcCtD
Naphazoline—Sweating—Mitoxantrone—breast cancer	0.000576	0.00336	CcSEcCtD
Naphazoline—Sweating—Irinotecan—breast cancer	0.000576	0.00336	CcSEcCtD
Naphazoline—Hypertension—Tamoxifen—breast cancer	0.000574	0.00336	CcSEcCtD
Naphazoline—Asthenia—Anastrozole—breast cancer	0.000569	0.00333	CcSEcCtD
Naphazoline—Asthenia—Letrozole—breast cancer	0.000569	0.00333	CcSEcCtD
Naphazoline—Erythema—Vinorelbine—breast cancer	0.000569	0.00332	CcSEcCtD
Naphazoline—Sweating—Gemcitabine—breast cancer	0.000561	0.00328	CcSEcCtD
Naphazoline—Discomfort—Tamoxifen—breast cancer	0.00056	0.00327	CcSEcCtD
Naphazoline—Headache—Exemestane—breast cancer	0.000559	0.00327	CcSEcCtD
Naphazoline—Dizziness—Ixabepilone—breast cancer	0.000557	0.00326	CcSEcCtD
Naphazoline—Hypertension—Goserelin—breast cancer	0.000549	0.0032	CcSEcCtD
Naphazoline—Erythema—Thiotepa—breast cancer	0.000544	0.00318	CcSEcCtD
Naphazoline—Lacrimation increased—Epirubicin—breast cancer	0.000543	0.00317	CcSEcCtD
Naphazoline—ADRA2A—endocrine gland—breast cancer	0.000542	0.0145	CbGeAlD
Naphazoline—Discomfort—Goserelin—breast cancer	0.000535	0.00312	CcSEcCtD
Naphazoline—Tension—Thiotepa—breast cancer	0.000533	0.00312	CcSEcCtD
Naphazoline—Nausea—Exemestane—breast cancer	0.00053	0.0031	CcSEcCtD
Naphazoline—Nervousness—Thiotepa—breast cancer	0.000528	0.00308	CcSEcCtD
Naphazoline—Headache—Ixabepilone—breast cancer	0.000528	0.00308	CcSEcCtD
Naphazoline—Terbinafine—CYP2D6—breast cancer	0.000525	0.136	CrCbGaD
Naphazoline—Hyperhidrosis—Tamoxifen—breast cancer	0.000525	0.00307	CcSEcCtD
Naphazoline—Dizziness—Anastrozole—breast cancer	0.000525	0.00307	CcSEcCtD
Naphazoline—Dizziness—Letrozole—breast cancer	0.000525	0.00307	CcSEcCtD
Naphazoline—Vision blurred—Thiotepa—breast cancer	0.000512	0.00299	CcSEcCtD
Naphazoline—Lacrimation increased—Doxorubicin—breast cancer	0.000503	0.00294	CcSEcCtD
Naphazoline—Hyperhidrosis—Goserelin—breast cancer	0.000501	0.00293	CcSEcCtD
Naphazoline—Nausea—Ixabepilone—breast cancer	0.000501	0.00292	CcSEcCtD
Naphazoline—Dizziness—Raloxifene—breast cancer	0.000498	0.00291	CcSEcCtD
Naphazoline—Headache—Letrozole—breast cancer	0.000497	0.0029	CcSEcCtD
Naphazoline—Headache—Anastrozole—breast cancer	0.000497	0.0029	CcSEcCtD
Naphazoline—Hyperglycaemia—Paclitaxel—breast cancer	0.000496	0.0029	CcSEcCtD
Naphazoline—Hypertension—Vinorelbine—breast cancer	0.000491	0.00287	CcSEcCtD
Naphazoline—Discomfort—Vinorelbine—breast cancer	0.000479	0.0028	CcSEcCtD
Naphazoline—Headache—Raloxifene—breast cancer	0.000472	0.00276	CcSEcCtD
Naphazoline—Headache—Idarubicin—breast cancer	0.000472	0.00276	CcSEcCtD
Naphazoline—Nausea—Anastrozole—breast cancer	0.000471	0.00275	CcSEcCtD
Naphazoline—Nausea—Letrozole—breast cancer	0.000471	0.00275	CcSEcCtD
Naphazoline—ADRA2C—lymph node—breast cancer	0.00047	0.0126	CbGeAlD
Naphazoline—Erythema—Mitoxantrone—breast cancer	0.000469	0.00274	CcSEcCtD
Naphazoline—Hypertension—Thiotepa—breast cancer	0.000469	0.00274	CcSEcCtD
Naphazoline—Somnolence—Goserelin—breast cancer	0.000461	0.00269	CcSEcCtD
Naphazoline—Erythema—Gemcitabine—breast cancer	0.000457	0.00267	CcSEcCtD
Naphazoline—Terbinafine—CYP3A4—breast cancer	0.000451	0.116	CrCbGaD
Naphazoline—Erythema—Fluorouracil—breast cancer	0.00045	0.00263	CcSEcCtD
Naphazoline—Nausea—Raloxifene—breast cancer	0.000447	0.00261	CcSEcCtD
Naphazoline—Nausea—Idarubicin—breast cancer	0.000447	0.00261	CcSEcCtD
Naphazoline—Vision blurred—Mitoxantrone—breast cancer	0.000442	0.00258	CcSEcCtD
Naphazoline—Asthenia—Chlorambucil—breast cancer	0.000438	0.00256	CcSEcCtD
Naphazoline—Vision blurred—Fluorouracil—breast cancer	0.000424	0.00248	CcSEcCtD
Naphazoline—Eye disorder—Paclitaxel—breast cancer	0.000411	0.0024	CcSEcCtD
Naphazoline—Hyperglycaemia—Capecitabine—breast cancer	0.000407	0.00238	CcSEcCtD
Naphazoline—Hypertension—Irinotecan—breast cancer	0.000405	0.00237	CcSEcCtD
Naphazoline—Hypertension—Mitoxantrone—breast cancer	0.000405	0.00237	CcSEcCtD
Naphazoline—Eye pain—Epirubicin—breast cancer	0.000403	0.00235	CcSEcCtD
Naphazoline—Asthenia—Vinblastine—breast cancer	0.000401	0.00234	CcSEcCtD
Naphazoline—Duloxetine—CYP2D6—breast cancer	0.000396	0.102	CrCbGaD
Naphazoline—Discomfort—Mitoxantrone—breast cancer	0.000395	0.00231	CcSEcCtD
Naphazoline—Discomfort—Irinotecan—breast cancer	0.000395	0.00231	CcSEcCtD
Naphazoline—Hypertension—Gemcitabine—breast cancer	0.000395	0.00231	CcSEcCtD
Naphazoline—Somnolence—Thiotepa—breast cancer	0.000394	0.0023	CcSEcCtD
Naphazoline—Asthenia—Tamoxifen—breast cancer	0.00039	0.00228	CcSEcCtD
Naphazoline—Discomfort—Gemcitabine—breast cancer	0.000385	0.00225	CcSEcCtD
Naphazoline—Erythema—Paclitaxel—breast cancer	0.000383	0.00224	CcSEcCtD
Naphazoline—Asthenia—Melphalan—breast cancer	0.000381	0.00223	CcSEcCtD
Naphazoline—Discomfort—Fluorouracil—breast cancer	0.000378	0.00221	CcSEcCtD
Naphazoline—Tension—Paclitaxel—breast cancer	0.000376	0.00219	CcSEcCtD
Naphazoline—ADRA2A—lymph node—breast cancer	0.000375	0.0101	CbGeAlD
Naphazoline—Eye pain—Doxorubicin—breast cancer	0.000373	0.00218	CcSEcCtD
Naphazoline—Asthenia—Goserelin—breast cancer	0.000372	0.00217	CcSEcCtD
Naphazoline—Nervousness—Paclitaxel—breast cancer	0.000372	0.00217	CcSEcCtD
Naphazoline—Hyperhidrosis—Mitoxantrone—breast cancer	0.00037	0.00216	CcSEcCtD
Naphazoline—Hyperhidrosis—Irinotecan—breast cancer	0.00037	0.00216	CcSEcCtD
Naphazoline—Dizziness—Vinblastine—breast cancer	0.00037	0.00216	CcSEcCtD
Naphazoline—Nausea—Chlorambucil—breast cancer	0.000362	0.00212	CcSEcCtD
Naphazoline—Vision blurred—Paclitaxel—breast cancer	0.000361	0.00211	CcSEcCtD
Naphazoline—Hyperhidrosis—Gemcitabine—breast cancer	0.000361	0.00211	CcSEcCtD
Naphazoline—Dizziness—Tamoxifen—breast cancer	0.000359	0.0021	CcSEcCtD
Naphazoline—Headache—Vinblastine—breast cancer	0.00035	0.00205	CcSEcCtD
Naphazoline—Eye disorder—Docetaxel—breast cancer	0.000348	0.00203	CcSEcCtD
Naphazoline—Dizziness—Goserelin—breast cancer	0.000343	0.002	CcSEcCtD
Naphazoline—Somnolence—Mitoxantrone—breast cancer	0.000341	0.00199	CcSEcCtD
Naphazoline—Somnolence—Irinotecan—breast cancer	0.000341	0.00199	CcSEcCtD
Naphazoline—Headache—Tamoxifen—breast cancer	0.00034	0.00199	CcSEcCtD
Naphazoline—Eye disorder—Capecitabine—breast cancer	0.000337	0.00197	CcSEcCtD
Naphazoline—Asthenia—Vinorelbine—breast cancer	0.000333	0.00195	CcSEcCtD
Naphazoline—Nausea—Vinblastine—breast cancer	0.000332	0.00194	CcSEcCtD
Naphazoline—Somnolence—Gemcitabine—breast cancer	0.000332	0.00194	CcSEcCtD
Naphazoline—Hypertension—Paclitaxel—breast cancer	0.000331	0.00193	CcSEcCtD
Naphazoline—Somnolence—Fluorouracil—breast cancer	0.000326	0.00191	CcSEcCtD
Naphazoline—Headache—Goserelin—breast cancer	0.000325	0.0019	CcSEcCtD
Naphazoline—Erythema—Docetaxel—breast cancer	0.000325	0.0019	CcSEcCtD
Naphazoline—Nausea—Tamoxifen—breast cancer	0.000323	0.00188	CcSEcCtD
Naphazoline—Discomfort—Paclitaxel—breast cancer	0.000322	0.00188	CcSEcCtD
Naphazoline—Asthenia—Thiotepa—breast cancer	0.000318	0.00186	CcSEcCtD
Naphazoline—Nausea—Melphalan—breast cancer	0.000316	0.00184	CcSEcCtD
Naphazoline—Erythema—Capecitabine—breast cancer	0.000314	0.00184	CcSEcCtD
Naphazoline—Nausea—Goserelin—breast cancer	0.000308	0.0018	CcSEcCtD
Naphazoline—Dizziness—Vinorelbine—breast cancer	0.000307	0.00179	CcSEcCtD
Naphazoline—Hyperhidrosis—Paclitaxel—breast cancer	0.000302	0.00176	CcSEcCtD
Naphazoline—Drowsiness—Methotrexate—breast cancer	0.000299	0.00175	CcSEcCtD
Naphazoline—Vision blurred—Capecitabine—breast cancer	0.000296	0.00173	CcSEcCtD
Naphazoline—Dizziness—Thiotepa—breast cancer	0.000293	0.00171	CcSEcCtD
Naphazoline—Headache—Vinorelbine—breast cancer	0.000291	0.0017	CcSEcCtD
Naphazoline—Sweating—Methotrexate—breast cancer	0.000287	0.00168	CcSEcCtD
Naphazoline—Hyperglycaemia—Epirubicin—breast cancer	0.000283	0.00166	CcSEcCtD
Naphazoline—Hypertension—Docetaxel—breast cancer	0.00028	0.00164	CcSEcCtD
Naphazoline—Drowsiness—Epirubicin—breast cancer	0.00028	0.00164	CcSEcCtD
Naphazoline—Headache—Thiotepa—breast cancer	0.000278	0.00162	CcSEcCtD
Naphazoline—Somnolence—Paclitaxel—breast cancer	0.000278	0.00162	CcSEcCtD
Naphazoline—Nausea—Vinorelbine—breast cancer	0.000276	0.00161	CcSEcCtD
Naphazoline—Asthenia—Mitoxantrone—breast cancer	0.000275	0.00161	CcSEcCtD
Naphazoline—Asthenia—Irinotecan—breast cancer	0.000275	0.00161	CcSEcCtD
Naphazoline—Hypertension—Capecitabine—breast cancer	0.000271	0.00158	CcSEcCtD
Naphazoline—Sweating—Epirubicin—breast cancer	0.000269	0.00157	CcSEcCtD
Naphazoline—Asthenia—Gemcitabine—breast cancer	0.000268	0.00156	CcSEcCtD
Naphazoline—Propranolol—CYP1A1—breast cancer	0.000265	0.0683	CrCbGaD
Naphazoline—Discomfort—Capecitabine—breast cancer	0.000264	0.00154	CcSEcCtD
Naphazoline—Nausea—Thiotepa—breast cancer	0.000264	0.00154	CcSEcCtD
Naphazoline—Hyperglycaemia—Doxorubicin—breast cancer	0.000262	0.00153	CcSEcCtD
Naphazoline—Drowsiness—Doxorubicin—breast cancer	0.000259	0.00151	CcSEcCtD
Naphazoline—Dizziness—Irinotecan—breast cancer	0.000253	0.00148	CcSEcCtD
Naphazoline—Eye disorder—Methotrexate—breast cancer	0.000251	0.00147	CcSEcCtD
Naphazoline—Sweating—Doxorubicin—breast cancer	0.000248	0.00145	CcSEcCtD
Naphazoline—Hyperhidrosis—Capecitabine—breast cancer	0.000248	0.00145	CcSEcCtD
Naphazoline—Dizziness—Fluorouracil—breast cancer	0.000243	0.00142	CcSEcCtD
Naphazoline—Headache—Mitoxantrone—breast cancer	0.00024	0.0014	CcSEcCtD
Naphazoline—Headache—Irinotecan—breast cancer	0.00024	0.0014	CcSEcCtD
Naphazoline—Somnolence—Docetaxel—breast cancer	0.000235	0.00138	CcSEcCtD
Naphazoline—Eye disorder—Epirubicin—breast cancer	0.000235	0.00137	CcSEcCtD
Naphazoline—Erythema—Methotrexate—breast cancer	0.000234	0.00137	CcSEcCtD
Naphazoline—Headache—Gemcitabine—breast cancer	0.000234	0.00137	CcSEcCtD
Naphazoline—Headache—Fluorouracil—breast cancer	0.00023	0.00134	CcSEcCtD
Naphazoline—Nausea—Mitoxantrone—breast cancer	0.000228	0.00133	CcSEcCtD
Naphazoline—Nausea—Irinotecan—breast cancer	0.000228	0.00133	CcSEcCtD
Naphazoline—Asthenia—Paclitaxel—breast cancer	0.000224	0.00131	CcSEcCtD
Naphazoline—Nausea—Gemcitabine—breast cancer	0.000222	0.00129	CcSEcCtD
Naphazoline—Vision blurred—Methotrexate—breast cancer	0.00022	0.00129	CcSEcCtD
Naphazoline—Erythema—Epirubicin—breast cancer	0.000219	0.00128	CcSEcCtD
Naphazoline—Nausea—Fluorouracil—breast cancer	0.000218	0.00127	CcSEcCtD
Naphazoline—Eye disorder—Doxorubicin—breast cancer	0.000217	0.00127	CcSEcCtD
Naphazoline—Tension—Epirubicin—breast cancer	0.000215	0.00125	CcSEcCtD
Naphazoline—Nervousness—Epirubicin—breast cancer	0.000213	0.00124	CcSEcCtD
Naphazoline—Dizziness—Paclitaxel—breast cancer	0.000207	0.00121	CcSEcCtD
Naphazoline—Vision blurred—Epirubicin—breast cancer	0.000206	0.0012	CcSEcCtD
Naphazoline—Erythema—Doxorubicin—breast cancer	0.000203	0.00118	CcSEcCtD
Naphazoline—Tension—Doxorubicin—breast cancer	0.000199	0.00116	CcSEcCtD
Naphazoline—Propranolol—CYP2D6—breast cancer	0.000197	0.0509	CrCbGaD
Naphazoline—Discomfort—Methotrexate—breast cancer	0.000197	0.00115	CcSEcCtD
Naphazoline—Nervousness—Doxorubicin—breast cancer	0.000197	0.00115	CcSEcCtD
Naphazoline—Headache—Paclitaxel—breast cancer	0.000196	0.00114	CcSEcCtD
Naphazoline—Vision blurred—Doxorubicin—breast cancer	0.000191	0.00111	CcSEcCtD
Naphazoline—Asthenia—Docetaxel—breast cancer	0.00019	0.00111	CcSEcCtD
Naphazoline—Hypertension—Epirubicin—breast cancer	0.000189	0.0011	CcSEcCtD
Naphazoline—Nausea—Paclitaxel—breast cancer	0.000186	0.00108	CcSEcCtD
Naphazoline—Hyperhidrosis—Methotrexate—breast cancer	0.000185	0.00108	CcSEcCtD
Naphazoline—Discomfort—Epirubicin—breast cancer	0.000184	0.00108	CcSEcCtD
Naphazoline—Asthenia—Capecitabine—breast cancer	0.000184	0.00107	CcSEcCtD
Naphazoline—Dizziness—Docetaxel—breast cancer	0.000175	0.00102	CcSEcCtD
Naphazoline—Hypertension—Doxorubicin—breast cancer	0.000175	0.00102	CcSEcCtD
Naphazoline—Hyperhidrosis—Epirubicin—breast cancer	0.000173	0.00101	CcSEcCtD
Naphazoline—Discomfort—Doxorubicin—breast cancer	0.00017	0.000995	CcSEcCtD
Naphazoline—Somnolence—Methotrexate—breast cancer	0.00017	0.000991	CcSEcCtD
Naphazoline—Dizziness—Capecitabine—breast cancer	0.00017	0.00099	CcSEcCtD
Naphazoline—Propranolol—CYP3A4—breast cancer	0.000169	0.0436	CrCbGaD
Naphazoline—Headache—Docetaxel—breast cancer	0.000166	0.000969	CcSEcCtD
Naphazoline—Headache—Capecitabine—breast cancer	0.000161	0.000938	CcSEcCtD
Naphazoline—Hyperhidrosis—Doxorubicin—breast cancer	0.00016	0.000933	CcSEcCtD
Naphazoline—Somnolence—Epirubicin—breast cancer	0.000159	0.000928	CcSEcCtD
Naphazoline—Nausea—Docetaxel—breast cancer	0.000157	0.000919	CcSEcCtD
Naphazoline—Nausea—Capecitabine—breast cancer	0.000152	0.00089	CcSEcCtD
Naphazoline—Somnolence—Doxorubicin—breast cancer	0.000147	0.000858	CcSEcCtD
Naphazoline—Propranolol—ABCB1—breast cancer	0.000141	0.0363	CrCbGaD
Naphazoline—Asthenia—Methotrexate—breast cancer	0.000137	0.0008	CcSEcCtD
Naphazoline—Asthenia—Epirubicin—breast cancer	0.000128	0.000749	CcSEcCtD
Naphazoline—Dizziness—Methotrexate—breast cancer	0.000126	0.000737	CcSEcCtD
Naphazoline—Headache—Methotrexate—breast cancer	0.00012	0.000698	CcSEcCtD
Naphazoline—Asthenia—Doxorubicin—breast cancer	0.000119	0.000693	CcSEcCtD
Naphazoline—Dizziness—Epirubicin—breast cancer	0.000118	0.00069	CcSEcCtD
Naphazoline—Nausea—Methotrexate—breast cancer	0.000113	0.000662	CcSEcCtD
Naphazoline—Headache—Epirubicin—breast cancer	0.000112	0.000654	CcSEcCtD
Naphazoline—Dizziness—Doxorubicin—breast cancer	0.000109	0.000638	CcSEcCtD
Naphazoline—Nausea—Epirubicin—breast cancer	0.000106	0.00062	CcSEcCtD
Naphazoline—Headache—Doxorubicin—breast cancer	0.000104	0.000605	CcSEcCtD
Naphazoline—Nausea—Doxorubicin—breast cancer	9.82e-05	0.000573	CcSEcCtD
Naphazoline—ADRA2B—Signaling Pathways—KIT—breast cancer	8.47e-06	0.000147	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—APC—breast cancer	8.47e-06	0.000147	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3CG—breast cancer	8.47e-06	0.000147	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—CAV1—breast cancer	8.44e-06	0.000146	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—H2AFX—breast cancer	8.44e-06	0.000146	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—IL2—breast cancer	8.43e-06	0.000146	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—E2F1—breast cancer	8.38e-06	0.000145	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—EGF—breast cancer	8.38e-06	0.000145	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—ESR1—breast cancer	8.37e-06	0.000145	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—PIK3CB—breast cancer	8.34e-06	0.000145	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PIK3CD—breast cancer	8.32e-06	0.000144	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—FN1—breast cancer	8.27e-06	0.000144	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—IL2—breast cancer	8.24e-06	0.000143	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—ALB—breast cancer	8.22e-06	0.000143	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TERT—breast cancer	8.21e-06	0.000143	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—HRAS—breast cancer	8.2e-06	0.000142	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NFKBIA—breast cancer	8.17e-06	0.000142	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—MAPK3—breast cancer	8.12e-06	0.000141	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NOTCH1—breast cancer	8.09e-06	0.00014	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—SPP1—breast cancer	8.05e-06	0.00014	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—CXCL8—breast cancer	8.01e-06	0.000139	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—FGFR1—breast cancer	7.98e-06	0.000138	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—BRAF—breast cancer	7.97e-06	0.000138	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—ERBB3—breast cancer	7.96e-06	0.000138	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FGFR2—breast cancer	7.95e-06	0.000138	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3CG—breast cancer	7.92e-06	0.000137	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—APC—breast cancer	7.92e-06	0.000137	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—KIT—breast cancer	7.92e-06	0.000137	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—NOS3—breast cancer	7.86e-06	0.000136	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—HIF1A—breast cancer	7.86e-06	0.000136	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—EGF—breast cancer	7.82e-06	0.000136	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IGF1—breast cancer	7.76e-06	0.000135	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—AKT2—breast cancer	7.75e-06	0.000135	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—EGFR—breast cancer	7.72e-06	0.000134	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3CG—breast cancer	7.69e-06	0.000133	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—LEP—breast cancer	7.67e-06	0.000133	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—IL2—breast cancer	7.66e-06	0.000133	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TERT—breast cancer	7.63e-06	0.000132	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CAV1—breast cancer	7.6e-06	0.000132	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—MAPK3—breast cancer	7.58e-06	0.000132	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—KDR—breast cancer	7.51e-06	0.00013	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3CD—breast cancer	7.45e-06	0.000129	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—BRAF—breast cancer	7.44e-06	0.000129	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FGFR1—breast cancer	7.41e-06	0.000129	CbGpPWpGaD
Naphazoline—ADRA2B—GPCR downstream signaling—PIK3CA—breast cancer	7.38e-06	0.000128	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—SERPINE1—breast cancer	7.37e-06	0.000128	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—ESR1—breast cancer	7.32e-06	0.000127	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—HIF1A—breast cancer	7.3e-06	0.000127	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—KRAS—breast cancer	7.29e-06	0.000127	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PIK3CB—breast cancer	7.25e-06	0.000126	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IGF1—breast cancer	7.25e-06	0.000126	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—AKT2—breast cancer	7.24e-06	0.000126	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—AKT1—breast cancer	7.24e-06	0.000126	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—FN1—breast cancer	7.23e-06	0.000125	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—EGFR—breast cancer	7.21e-06	0.000125	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PTGS2—breast cancer	7.19e-06	0.000125	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NFKBIA—breast cancer	7.15e-06	0.000124	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—LEP—breast cancer	7.12e-06	0.000124	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NOTCH1—breast cancer	7.08e-06	0.000123	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CAV1—breast cancer	7.06e-06	0.000122	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—NOS3—breast cancer	7.03e-06	0.000122	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—KDR—breast cancer	6.98e-06	0.000121	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3CD—breast cancer	6.96e-06	0.000121	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—APC—breast cancer	6.92e-06	0.00012	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—KIT—breast cancer	6.92e-06	0.00012	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3CG—breast cancer	6.92e-06	0.00012	CbGpPWpGaD
Naphazoline—ADRA2C—GPCR downstream signaling—PIK3CA—breast cancer	6.89e-06	0.00012	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—SERPINE1—breast cancer	6.88e-06	0.000119	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—EGF—breast cancer	6.84e-06	0.000119	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—KRAS—breast cancer	6.81e-06	0.000118	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—ESR1—breast cancer	6.8e-06	0.000118	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3CD—breast cancer	6.76e-06	0.000117	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FN1—breast cancer	6.72e-06	0.000117	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—PIK3CA—breast cancer	6.7e-06	0.000116	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MDM2—breast cancer	6.67e-06	0.000116	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—ALB—breast cancer	6.67e-06	0.000116	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—RAF1—breast cancer	6.65e-06	0.000115	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NFKBIA—breast cancer	6.64e-06	0.000115	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—MAPK3—breast cancer	6.63e-06	0.000115	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—RELA—breast cancer	6.62e-06	0.000115	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—ERBB2—breast cancer	6.58e-06	0.000114	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NOTCH1—breast cancer	6.58e-06	0.000114	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NOS3—breast cancer	6.57e-06	0.000114	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—BRAF—breast cancer	6.5e-06	0.000113	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3CB—breast cancer	6.49e-06	0.000113	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MTOR—breast cancer	6.49e-06	0.000113	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—APC—breast cancer	6.43e-06	0.000112	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3CG—breast cancer	6.43e-06	0.000112	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—KIT—breast cancer	6.43e-06	0.000112	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—NOS3—breast cancer	6.38e-06	0.000111	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—EGF—breast cancer	6.36e-06	0.00011	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IGF1—breast cancer	6.34e-06	0.00011	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—AKT2—breast cancer	6.33e-06	0.00011	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—EGFR—breast cancer	6.3e-06	0.000109	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PTEN—breast cancer	6.27e-06	0.000109	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—PIK3CA—breast cancer	6.26e-06	0.000109	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CXCL8—breast cancer	6.24e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MDM2—breast cancer	6.23e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—RAF1—breast cancer	6.21e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—HRAS—breast cancer	6.2e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—RELA—breast cancer	6.19e-06	0.000107	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	6.16e-06	0.000107	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—ERBB2—breast cancer	6.15e-06	0.000107	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CDKN1B—breast cancer	6.09e-06	0.000106	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	6.08e-06	0.000106	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MTOR—breast cancer	6.07e-06	0.000105	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3CB—breast cancer	6.07e-06	0.000105	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—BRAF—breast cancer	6.04e-06	0.000105	CbGpPWpGaD
Naphazoline—ADRA2B—GPCR downstream signaling—AKT1—breast cancer	6.03e-06	0.000105	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	6.03e-06	0.000105	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	6.02e-06	0.000104	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CASP3—breast cancer	5.97e-06	0.000104	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IL2—breast cancer	5.96e-06	0.000103	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—KRAS—breast cancer	5.96e-06	0.000103	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—IL6—breast cancer	5.93e-06	0.000103	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3CB—breast cancer	5.89e-06	0.000102	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IGF1—breast cancer	5.89e-06	0.000102	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AKT2—breast cancer	5.88e-06	0.000102	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—EGFR—breast cancer	5.86e-06	0.000102	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PTGS2—breast cancer	5.84e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CXCL8—breast cancer	5.83e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CCND1—breast cancer	5.81e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—JUN—breast cancer	5.8e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—HRAS—breast cancer	5.79e-06	0.0001	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CTNNB1—breast cancer	5.76e-06	9.99e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NOS3—breast cancer	5.74e-06	9.97e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CDKN1B—breast cancer	5.69e-06	9.88e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	5.65e-06	9.81e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MMP9—breast cancer	5.64e-06	9.79e-05	CbGpPWpGaD
Naphazoline—ADRA2C—GPCR downstream signaling—AKT1—breast cancer	5.63e-06	9.77e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CDKN1A—breast cancer	5.62e-06	9.76e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PTEN—breast cancer	5.61e-06	9.74e-05	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	5.6e-06	9.71e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	5.59e-06	9.7e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CASP3—breast cancer	5.58e-06	9.68e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IL2—breast cancer	5.57e-06	9.66e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—IL6—breast cancer	5.54e-06	9.62e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—KRAS—breast cancer	5.53e-06	9.6e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MAPK8—breast cancer	5.49e-06	9.52e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—AKT1—breast cancer	5.47e-06	9.5e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	5.47e-06	9.49e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MDM2—breast cancer	5.45e-06	9.46e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—RAF1—breast cancer	5.43e-06	9.42e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CCND1—breast cancer	5.43e-06	9.42e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—JUN—breast cancer	5.42e-06	9.4e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—RELA—breast cancer	5.41e-06	9.38e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CTNNB1—breast cancer	5.38e-06	9.33e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—ERBB2—breast cancer	5.37e-06	9.32e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NOS3—breast cancer	5.34e-06	9.26e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	5.3e-06	9.2e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MTOR—breast cancer	5.3e-06	9.2e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MMP9—breast cancer	5.27e-06	9.15e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CDKN1A—breast cancer	5.25e-06	9.11e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PTEN—breast cancer	5.24e-06	9.09e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—SRC—breast cancer	5.2e-06	9.03e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MAPK8—breast cancer	5.13e-06	8.9e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—AKT1—breast cancer	5.11e-06	8.87e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CXCL8—breast cancer	5.1e-06	8.84e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PTEN—breast cancer	5.09e-06	8.83e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	5.08e-06	8.82e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—VEGFA—breast cancer	5.07e-06	8.79e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MDM2—breast cancer	5.06e-06	8.79e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—HRAS—breast cancer	5.06e-06	8.78e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—RAF1—breast cancer	5.05e-06	8.76e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—RELA—breast cancer	5.02e-06	8.72e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—STAT3—breast cancer	5.02e-06	8.71e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—ERBB2—breast cancer	4.99e-06	8.66e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	4.98e-06	8.63e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	4.93e-06	8.55e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MTOR—breast cancer	4.93e-06	8.55e-05	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	4.92e-06	8.54e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CASP3—breast cancer	4.88e-06	8.46e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL2—breast cancer	4.87e-06	8.45e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—SRC—breast cancer	4.86e-06	8.43e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—IL6—breast cancer	4.85e-06	8.41e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MAPK3—breast cancer	4.79e-06	8.32e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CCND1—breast cancer	4.75e-06	8.24e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—JUN—breast cancer	4.74e-06	8.22e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CXCL8—breast cancer	4.73e-06	8.21e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—VEGFA—breast cancer	4.73e-06	8.21e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—HRAS—breast cancer	4.7e-06	8.16e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	4.7e-06	8.16e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—STAT3—breast cancer	4.69e-06	8.13e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MYC—breast cancer	4.66e-06	8.09e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—TGFB1—breast cancer	4.65e-06	8.07e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	4.62e-06	8.02e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MMP9—breast cancer	4.61e-06	8e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	4.59e-06	7.97e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PTEN—breast cancer	4.58e-06	7.95e-05	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	4.57e-06	7.94e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—EGFR—breast cancer	4.56e-06	7.91e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CASP3—breast cancer	4.53e-06	7.86e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL2—breast cancer	4.52e-06	7.85e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—IL6—breast cancer	4.5e-06	7.81e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MAPK8—breast cancer	4.48e-06	7.78e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MAPK3—breast cancer	4.48e-06	7.77e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—AKT1—breast cancer	4.47e-06	7.76e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PIK3CA—breast cancer	4.42e-06	7.67e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CCND1—breast cancer	4.41e-06	7.65e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—JUN—breast cancer	4.4e-06	7.64e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	4.37e-06	7.58e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MYC—breast cancer	4.36e-06	7.56e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—TGFB1—breast cancer	4.35e-06	7.54e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—KRAS—breast cancer	4.31e-06	7.48e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MMP9—breast cancer	4.28e-06	7.43e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	4.27e-06	7.4e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—EGFR—breast cancer	4.26e-06	7.39e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PTEN—breast cancer	4.26e-06	7.39e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—SRC—breast cancer	4.25e-06	7.37e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MAPK8—breast cancer	4.16e-06	7.23e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—AKT1—breast cancer	4.15e-06	7.21e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—VEGFA—breast cancer	4.14e-06	7.18e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—STAT3—breast cancer	4.1e-06	7.11e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—KRAS—breast cancer	4.02e-06	6.98e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	3.96e-06	6.87e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—SRC—breast cancer	3.95e-06	6.85e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MAPK3—breast cancer	3.92e-06	6.79e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—VEGFA—breast cancer	3.85e-06	6.67e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—TP53—breast cancer	3.83e-06	6.64e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MYC—breast cancer	3.81e-06	6.61e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—STAT3—breast cancer	3.81e-06	6.61e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TGFB1—breast cancer	3.8e-06	6.59e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—EGFR—breast cancer	3.72e-06	6.46e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	3.7e-06	6.42e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—HRAS—breast cancer	3.66e-06	6.35e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MAPK3—breast cancer	3.64e-06	6.31e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—AKT1—breast cancer	3.61e-06	6.27e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3CA—breast cancer	3.59e-06	6.23e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—TP53—breast cancer	3.58e-06	6.21e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MYC—breast cancer	3.54e-06	6.14e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TGFB1—breast cancer	3.53e-06	6.12e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—KRAS—breast cancer	3.52e-06	6.1e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IL6—breast cancer	3.51e-06	6.08e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—EGFR—breast cancer	3.46e-06	6e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—HRAS—breast cancer	3.42e-06	5.94e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IL6—breast cancer	3.27e-06	5.68e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—KRAS—breast cancer	3.27e-06	5.67e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—AKT1—breast cancer	3.23e-06	5.61e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	3.23e-06	5.61e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TP53—breast cancer	3.13e-06	5.43e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—AKT1—breast cancer	3.02e-06	5.24e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	3e-06	5.21e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—HRAS—breast cancer	2.99e-06	5.19e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—AKT1—breast cancer	2.93e-06	5.09e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TP53—breast cancer	2.91e-06	5.04e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL6—breast cancer	2.86e-06	4.97e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—HRAS—breast cancer	2.78e-06	4.82e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL6—breast cancer	2.66e-06	4.61e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—AKT1—breast cancer	2.64e-06	4.58e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AKT1—breast cancer	2.45e-06	4.26e-05	CbGpPWpGaD
